## Saúl Berman

Contact information	Av Medrano 134 floor 6 Caba. Buenos Aires. Argentina. Zip Code C1179AAB .
	nhono +54 11 4093 1590 phono 5401140015045
	<ul> <li>phone +54 11 4983 1589. phone 5491149915945</li> </ul>
	Email: saulberman56@hotmail.com
Education	Physician, University of Tucumán 1983
	Improvement in endoscopy. Hadassah Hospital. JerusalemIsrael, 1993
	Specialist in gastroenterology, Argentine Society of Gastroenterology 2003.
	Basic Training for Medical Research and Good Clinical Practices. Zieher Foundation
	2008.
	Administration of Quintiles Medical Research Centers. 2008
	Provision 6677/10 ANMAT, Novo Nordisk 2015
	Good clinical practices, Quintiles 2015
	Good clinical practices and 6677 ANMAT. Latam. June 2019
	• Diploma in Good Practices in Biomedical Research. University of São Paulo. Tucuman.
	Approved by resolution N 0875/2020; August 2020 to July 2021. Workload 238 hours
Current employment	IMOBA SRL Medical Research
information	Av Medrano 134 floor 6 CABA
	Medical Director and researcher from 2009 to the present.
	Surgical Institute of Callao     Head of endoscopy. Since 2002.
	Anchorena Recoleta Sanatorium
	Head of endoscopy. Since 2008.
	Anchorena San Martin Sanatorium
	Head of endoscopy. Since 2018.
License	M.N 67962

## Clinical studies experience

- ➤ H9X-MC-GBDC The impact of LY2189265 versus metformin on glycemic control in early type 2 diabetes mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3). 3]). Sub-Investigator from 2011 to 2012.
- ➤ SUSTAIN 2: The efficacy and safety of once-weekly administered semaglutide versus once-daily administered sitagliptin as an adjunct to metformin and/or TZDs in patients with type 2 diabetes from April 2014 through 2015. Phase 3, Sub-investigator.
- ➤ SUSTAIN 3: The efficacy and safety of semaglutide administered once weekly compared with ER 2 mg exenatide administered once weekly as an adjunct to 1-2 oral agents in patients with type 2 diabetes Phase 3 From April 2014 to 2015. Sub Investigator.